newsfilter
← Latest News
Business Wire·

Alpine Immune Sciences Presents New Translational Data on Povetacicept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023

--Povetacicept Superior to Wild-Type TACI-Fc and B-cell Depletion in a Preclinical Model of Lupus-- -- Initiation of Phase 2 SLE Study Planned for 2H 2024 -- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading